D.E. Shaw & Co’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-18,363
Closed -$202K 3653
2017
Q1
$202K Sell
18,363
-142,196
-89% -$1.65M ﹤0.01% 3118
2016
Q4
$2.18M Buy
160,559
+58,058
+57% +$810K ﹤0.01% 1932
2016
Q3
$1.26M Buy
102,501
+75,854
+285% +$894K ﹤0.01% 2244
2016
Q2
$292K Sell
26,647
-51,444
-66% -$576K ﹤0.01% 3030
2016
Q1
$854K Buy
78,091
+60,870
+353% +$769K ﹤0.01% 2462
2015
Q4
$298K Sell
17,221
-160,955
-90% -$2.89M ﹤0.01% 3365
2015
Q3
$3.54M Buy
178,176
+120,521
+209% +$2.76M 0.01% 1658
2015
Q2
$947K Buy
57,655
+32,823
+132% +$569K ﹤0.01% 2746
2015
Q1
$386K Buy
24,832
+8,093
+48% +$125K ﹤0.01% 3191
2014
Q4
$239K Buy
+16,739
New +$177K ﹤0.01% 3739
2014
Q2
Sell
-13,482
Closed -$96K 4731
2014
Q1
$96K Sell
13,482
-71,759
-84% -$614K ﹤0.01% 4177
2013
Q4
$801K Sell
85,241
-18,615
-18% -$133K ﹤0.01% 3356
2013
Q3
$648K Sell
103,856
-26,273
-20% -$164K ﹤0.01% 3389
2013
Q2
$856K Buy
+130,129
New +$1.03M ﹤0.01% 2846

Other funds holding SCMP

D.E. Shaw & Co's SCMP Position: Q2 2017 in Review

D.E. Shaw & Co sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2017, closing a stake of 18,363 shares — an estimated $202K sold.

D.E. Shaw & Co first reported a position in SCMP in Q2 2013 and held it in 14 quarters. The position peaked at $3.54M in Q3 2015. 167 funds tracked by Wall St. Rank hold SCMP as of Q2 2017.

  • D.E. Shaw & Co reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • D.E. Shaw & Co sold 18,363 Sucampo Pharmaceuticals, Inc. shares in Q2 2017, an estimated $202K.
  • D.E. Shaw & Co first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
  • D.E. Shaw & Co's Sucampo Pharmaceuticals, Inc. position peaked at $3.54M in Q3 2015.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2017.

Based on D.E. Shaw & Co's 13F filing for Q2 2017, filed 14 Aug 2017.